Plus Therapeutics

Advanced Radiotherapeutics Will Capitalize On Aging Cancer Demographics

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

19 Aug 25

Updated

19 Aug 25

AnalystHighTarget's Fair Value

US$20.50

97.6% undervalued

19 Aug

US$0.48

-66.9%

-15.8%

Author's Valuation

US$20.5

97.6% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$20.5

97.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

65.12%

Biotech revenue growth rate

11.72%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$11.61m

Earnings '28

468.87x

PE Ratio '28

US$5.44b

Market Cap '28

US$5.44b

Market Cap '28

218.08m

No. shares '28

US$24.96

Share Price '28

US$24.96 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$20.50

Fair Value '25